Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Kuo-Liang Wei"'
Autor:
Chun-Hsien Chen, Yung-Yu Hsieh, Wei-Ming Chen, Chien-Heng Shen, Kuo-Liang Wei, Kao-Chi Chang, Yuan-Jie Ding, Sheng-Nan Lu, Chao-Hung Hung, Te-Sheng Chang
Publikováno v:
Diagnostics, Vol 14, Iss 2, p 213 (2024)
Few studies have reported weight gain in patients with hepatitis C virus (HCV) infection treated with direct-acting antiviral agents (DAAs). This retrospective cohort study identified factors associated with substantial weight gain after DAA treatmen
Externí odkaz:
https://doaj.org/article/33b5deec26a54961acb36f5de2e5ac2f
Autor:
Yu-Ting Huang, Yung-Yu Hsieh, Wei-Ming Chen, Shui-Yi Tung, Kuo-Liang Wei, Chen-Heng Shen, Kao-Chi Chang, Chung-Kuang Lu, Chih-Wei Yen, Sheng-Nan Lu, Chao-Hung Hung, Te-Sheng Chang
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Introduction Real-world data regarding the impact of hepatic fibrosis on the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) treatment is limited in the Asian population. Methods We analyzed data for all 823 patients with hepatitis C virus
Externí odkaz:
https://doaj.org/article/7ff65f631718492990e481431278f20a
Autor:
Kao-Chi Chang, Shui-Yi Tung, Kuo-Liang Wei, Chen-Heng Shen, Yung-Yu Hsieh, Wei-Ming Chen, Yi-Hsing Chen, Chun-Hsien Chen, Chi-Wei Yen, Huang-Wei Xu, Wei-Lin Tung, Chao-Hung Hung, Sheng-Nan Lu, Te-Sheng Chang
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Clinical trials showed pangenotypic direct-acting antivirals’ (DAAs) excellent efficacy and safety when treating hepatitis C virus (HCV). Two pangenotypic regimens were examined, glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/velpatasvi
Externí odkaz:
https://doaj.org/article/c3f883780e4f498eae4652d3f293f1fe
Autor:
Wei-Ming Chen, Kuo-Liang Wei, Shui-Yi Tung, Chien-Heng Shen, Te-Sheng Chang, Chih-Wei Yen, Yung-Yu Hsieh, Wen Nan Chiu, Jin Hung Hu, Sheng-Nan Lu, Chao-Hung Hung
Publikováno v:
Journal of the Formosan Medical Association, Vol 119, Iss 11, Pp 1593-1600 (2020)
Background: The real-world data of glecaprevir/pibrentasvir (GLE/PIB) therapy for patients with chronic hepatitis C virus (HCV) genotype 2 infection remained limited. We aimed to evaluate the possible predictors of virological failure and side effect
Externí odkaz:
https://doaj.org/article/c8d9459c54c346d5a854dc95ce01b216
Autor:
Chi-Ching Chen, Shui-Yi Tung, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Huang-Wei Xu, Chih-Wei Yen, Yi-Hsing Chen, Sheng-Nan Lu, Chao-Hung Hung
Publikováno v:
Journal of the Formosan Medical Association, Vol 119, Iss 1, Pp 532-537 (2020)
Background/Purpose: The major dose-limiting toxicity of ribavirin is hemolytic anemia. We investigated the incidence, risk factors and impact on virological response of anemia in chronic hepatitis C genotype 2 patients receiving sofosbuvir plus ribav
Externí odkaz:
https://doaj.org/article/13086ad5913a4056b336bce10fbc35cb
Autor:
Chun-Hsien Chen, Chien-Heng Shen, Kuo-Liang Wei, Huang-Wei Xu, Wei-Ming Chen, Kao-Chi Chang, Yu-Ting Huang, Yung-Yu Hsieh, Sheng-Nan Lu, Chao-Hung Hung, Te-Sheng Chang
Publikováno v:
Diagnostics, Vol 13, Iss 3, p 473 (2023)
The findings regarding changes in renal function in patients with hepatitis C virus (HCV) infection treated with direct-acting antivirals (DAAs) are controversial. This study attempted to identify the factors associated with the large decline in rena
Externí odkaz:
https://doaj.org/article/0ec09dafb59745aaaaea06700fc8f38d
Autor:
Yung-Yu Hsieh, Wei-Ming Chen, Kao-Chi Chang, Te-Sheng Chang, Chao-Hung Hung, Yao-Hsu Yang, Shui-Yi Tung, Kuo-Liang Wei, Chen-Heng Shen, Cheng-Shyong Wu, Yuan-Jie Ding, Jing-Hong Hu, Yu-Ting Huang, Meng-Hung Lin, Chung-Kuang Lu, Yi-Hsiung Lin, Ming-Shyan Lin
Publikováno v:
Viruses, Vol 15, Iss 1, p 252 (2023)
The real-world benefits of direct-acting antiviral (DAA)-induced sustained virologic response (SVR) on the de novo occurrence and progression of esophageal varices (EV) remain unclear in patients with hepatitis C virus (HCV)-related liver cirrhosis (
Externí odkaz:
https://doaj.org/article/a20746258a254b379145f32cfef4b4a5
Autor:
Kuo-Liang Wei, Jian-Liang Chou, Yin-Chen Chen, Jie-Ting Low, Guan-Ling Lin, Jing-Lan Liu, Te-Sheng Chang, Wei-Ming Chen, Yung-Yu Hsieh, Pearlly S. Yan, Yu-Ming Chuang, Jora M. J. Lin, Shu-Fen Wu, Ming-Ko Chiang, Chin Li, Cheng-Shyong Wu, Michael W. Y. Chan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeThe purpose of this study was to identify genes that were epigenetically silenced by STAT3 in gastric cancer.MethodsMBDcap-Seq and expression microarray were performed to identify genes that were epigenetically silenced in AGS gastric cancer c
Externí odkaz:
https://doaj.org/article/5c1eb056c1a4416dbfb061e85c05283d
Autor:
Sheng Feng Lin, Shui-Yi Tung, Kuo-Liang Wei, Chien-Hung Chen, Tsung-Hui Hu, Chien Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Chih-Wei Yen, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229994 (2020)
BACKGROUND:Hepatitis C virus core antigen (HCV Ag) assay has been proposed as a more economical alternative to HCV RNA detection. This study aimed to investigate the clinical utility of HCV Ag assay in the monitoring of direct-acting antivirals (DAAs
Externí odkaz:
https://doaj.org/article/de2b29633d924f9fb82b42df28dd8cc2
Autor:
Kuo-Liang Wei, Jian-Liang Chou, Yin-Chen Chen, Hongchuan Jin, Yu-Min Chuang, Cheng-Shyong Wu, Michael W Y Chan
Publikováno v:
PLoS ONE, Vol 14, Iss 6, p e0218338 (2019)
Gastric cancer is a leading cause of cancer worldwide. Our previous studies showed that aberrant activation of JAK/STAT3 signaling confer epigenetically silences STAT3 target genes in gastric cancer. To further investigate the clinical significance o
Externí odkaz:
https://doaj.org/article/d3e70c3b5fea42f9abdab44c7795123b